
News|Articles|July 1, 2012
Pipeline Preview
Recent FDA action (through June 2012) related to, Darunavir, Prezista, Janssen Therapeutics, Ridaforolimus, Merck, Tafamidis meglumine, Pfizer, mechlorethamine, Ceptaris Therapeutics, AVP-923, Avanir Pharmaceuticals, NKTR-181, Nektar Therapeutics, EDI200, Edimer Pharmaceuticals, Galeterone, TOK-001, Tokai Pharmaceuticals, Butoconazole nitrate 2% vaginal cream, Gynazole-1, Perrigo
Advertisement
Complete response
Priority review
Fast-track designation
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Studies of tafasitamab and epcoritamab
2
Dosing schedules of combination approaches
3
States push for new PBM reporting rules | PBMI 2026
4
A conversation with Julia S. Feldman, Ph.D., about taking impairment and context into consideration when diagnosing preschoolers with ADHD
5
























